Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26965355 | 1.00 | FDPS (0.44) | FDPSCYP3A4HSPA5HSPA2ACACB | |
| SCHEMBL9849647 | 0.84 | HSPA5 (0.43) | FDPSCYP3A4HSPA5HSPA2ACACB | |
| SCHEMBL29637208 | 0.80 | CYP3A4 (0.56) | CYP3A4 | |
| SCHEMBL5869892 | 0.76 | FDPS (0.43) | FDPSHSPA5HSPA2FFAR2ALDH1A1 | |
| SCHEMBL26965347 | 0.74 | NPC1 (0.37) | ALDH1A1LMNA | |
| SCHEMBL27135267 | 0.74 | NPC1 (0.37) | ALDH1A1LMNA | |
| SCHEMBL13370727 | 0.73 | FDPS (0.53) | FDPSACACBPKMALDH1A1LMNA | |
| SCHEMBL29675493 | 0.73 | ACACB (0.59) | FDPSACACBALDH1A1 | |
| SCHEMBL104654 | 0.72 | — | — | |
| SCHEMBL7179963 | 0.71 | FDPS (0.44) | FDPSCYP3A4HSPA5ACACBFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | FDPS 700/4885CYP3A4 4041/4885HSPA5 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.